Paper Summary
Paperzilla title
Can an Allergy Nose Spray Help Prevent Long COVID? Small Study Suggests a Possibility
This small study investigated whether an intranasal chlorpheniramine spray, typically used for allergies, could help prevent or mitigate post-acute sequelae of SARS-CoV-2 infection (PASC), also known as "long COVID." The study involved a small number of participants from two previous clinical trials and found that those who received the spray reported significantly fewer long-COVID symptoms. However, it is important to note the small sample size and the lack of standardized treatment protocols limit the reliability of the findings.
Possible Conflicts of Interest
This research was funded by Dr. Ferrer Biopharma, which could potentially introduce a conflict of interest. No other conflicts were identified.
Identified Weaknesses
This study had a relatively small sample size, which limits the generalizability of the findings.
Lack of Standardized Treatment
Participants in both the iCPM and placebo groups received other treatments, such as antivirals, which could have influenced the results and made it challenging to isolate the effect of iCPM.
Variable Treatment Timing
The timing of iCPM treatment initiation varied between participants, which could have affected the outcomes.
Rating Explanation
This study presents some interesting preliminary findings, but the small sample size and other methodological limitations warrant a cautious interpretation and a rating of 3. Larger, more rigorous studies are needed to confirm these results.
Good to know
This is our free standard analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
File Information
Original Title:
Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies
Uploaded:
August 26, 2025 at 05:22 PM
© 2025 Paperzilla. All rights reserved.